North America Stem Cell Market Forecast 2022-2030
Description
North America Stem Cell Market Forecast 2022-2030KEY FINDINGS
The North America stem cell market is predicted to garner a CAGR of 9.01% during the forecasted years 2022 to 2030. Some of the leading aspects propelling the regional market’s growth include public awareness regarding the therapeutic potential of stem cell products, increasing public-private funding and investments in stem cell-based research, as well as technological advancements in stem cell manufacturing and preservation.
MARKET INSIGHTS
The North America stem cell market growth evaluation entails the study of Canada and the United States. As per the Canadian Institutes of Health Research, over 300,000 Canadians were estimated to have type 1 diabetes (T1D) in the year 2020. T1D is characterized as an autoimmune condition with no known origins or treatments that impacts the pancreatic beta cells responsible for the creation of insulin. However, owing to a ground-breaking new stem cell-based therapy developed by Canadian researchers, it is possible that individuals with type 1 diabetes may no longer need insulin injections.
In this regard, a team of researchers from the Vancouver Coastal Health (VCH), as well as the University of British Columbia, conducted a pioneering study demonstrating how a small implant injected with stem cells can potentially assist the body in producing insulin on its own. Moreover, given the funding of $1 million from the country’s Stem Cell Network, one of the first genetically engineered cell replacement treatments for type 1 diabetes is set to be tested in a clinical trial in 2022. Therefore, these factors are anticipated to facilitate the stem cell market growth in North America during the forecast period.
COMPETITIVE INSIGHTS
Key firms operating in the market are AllCells LLC, GE Healthcare, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
The North America stem cell market is predicted to garner a CAGR of 9.01% during the forecasted years 2022 to 2030. Some of the leading aspects propelling the regional market’s growth include public awareness regarding the therapeutic potential of stem cell products, increasing public-private funding and investments in stem cell-based research, as well as technological advancements in stem cell manufacturing and preservation.
MARKET INSIGHTS
The North America stem cell market growth evaluation entails the study of Canada and the United States. As per the Canadian Institutes of Health Research, over 300,000 Canadians were estimated to have type 1 diabetes (T1D) in the year 2020. T1D is characterized as an autoimmune condition with no known origins or treatments that impacts the pancreatic beta cells responsible for the creation of insulin. However, owing to a ground-breaking new stem cell-based therapy developed by Canadian researchers, it is possible that individuals with type 1 diabetes may no longer need insulin injections.
In this regard, a team of researchers from the Vancouver Coastal Health (VCH), as well as the University of British Columbia, conducted a pioneering study demonstrating how a small implant injected with stem cells can potentially assist the body in producing insulin on its own. Moreover, given the funding of $1 million from the country’s Stem Cell Network, one of the first genetically engineered cell replacement treatments for type 1 diabetes is set to be tested in a clinical trial in 2022. Therefore, these factors are anticipated to facilitate the stem cell market growth in North America during the forecast period.
COMPETITIVE INSIGHTS
Key firms operating in the market are AllCells LLC, GE Healthcare, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
135 Pages
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Surging Demand For Stem Cells In Regenerative Medicine
- 3.1.2. Growing R&D Investments In Stem Cell Therapies & Research
- 3.1.3. Rising Awareness About Umbilical Cord Stem Cells
- 3.1.4. Reduced Risk Of Tissue Rejection In Transplants
- 3.2. Key Restraints
- 3.2.1. Absence Of A Well-defined Regulatory Framework For Stem Cell Therapy
- 3.2.2. High Costs Associated With Stem Cell Procedures
- 3.2.3. Ethical Issues And Social Complexities
- 3.2.4. Less Responsiveness In Developed Economies
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Stem Cell Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Vendor Landscape
- 4.6. Value Chain Analysis
- 4.7. Key Buying Criteria
- 4.7.1. Price
- 4.7.2. Efficacy
- 4.7.3. Application And Effectiveness
- 4.7.4. Accuracy
- 4.8. Regulatory Framework
- 5. Market By Therapeutic Application
- 5.1. Orthopedic Treatments
- 5.2. Injuries & Wounds
- 5.3. Oncology Disorders
- 5.4. Cardiovascular Disorders
- 5.5. Neurological Disorders
- 5.6. Diabetes
- 5.7. Other Therapeutic Applications
- 6. Market By Product
- 6.1. Adult Stem Cell
- 6.1.1. Hematopoietic Stem Cell
- 6.1.2. Neural Stem Cell
- 6.1.3. Umbilical Cord Stem Cell
- 6.1.4. Mesenchymal Stem Cell
- 6.1.5. Dental Stem Cell
- 6.2. Human Embryonic Stem Cell
- 6.3. Pluripotent
- 6.4. Mouse/Rat Neural
- 7. Market By Technology
- 7.1. Cell Acquisition
- 7.1.1. Bone Marrow Harvest
- 7.1.2. Umbilical Cord
- 7.1.3. Apheresis
- 7.2. Cell Production
- 7.2.1. Therapeutic Cloning
- 7.2.2. In Vitro Fertilization (Ivf)
- 7.2.3. Cell Culture
- 7.2.4. Isolation
- 7.3. Cryopreservation
- 7.4. Expansion & Sub-culture
- 8. Market By Application
- 8.1. Regenerative Medicine
- 8.2. Drug Discovery And Development
- 9. Market By Treatment Type
- 9.1. Allogeneic Stem Cell Therapy
- 9.2. Autologic Stem Cell Therapy
- 9.3. Syngeneic Stem Cell Therapy
- 10. Geographical Analysis
- 10.1. North America
- 10.1.1. Market Size & Estimates
- 10.1.2. Key Growth Enablers
- 10.1.3. Key Challenges
- 10.1.4. Key Players
- 10.1.5. Country Analysis
- 10.1.5.1. United States
- 10.1.5.2. Canada
- 11. Competitive Landscape
- 11.1. Key Strategic Developments
- 11.1.1. Acquisitions
- 11.1.2. Partnerships
- 11.2. Company Profiles
- 11.2.1. Allcells Llc
- 11.2.2. Becton, Dickinson And Company (Bd)
- 11.2.3. Corning Inc
- 11.2.4. Ge Healthcare
- 11.2.5. International Stem Cell Corporation
- 11.2.6. Lorem Cytori Inc
- 11.2.7. Merck Kgaa (Sigma Aldrich)
- 11.2.8. Miltenyi Biotec
- 11.2.9. Pluri Inc
- 11.2.10. Qiagen
- 11.2.11. Smith+Nephew Plc
- 11.2.12. Stemcell Technologies Inc
- 11.2.13. Stryker Corporation
- 11.2.14. Takara Holdings Inc
- 11.2.15. Thermo Fisher Scientific Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
